The Funding and Costs of ALS Research

Published on January 30, 2026

The economics of ALS research reflect a critical balance between rising healthcare costs, substantial research investments, and the pursuit of effective treatments. In 2025, global ALS research funding exceeds $1 billion annually, driven by governments, pharmaceutical companies, and philanthropy seeking to reduce the disease’s multibillion-dollar societal burden. While ALS drug development is expensive and high-risk, innovations such as platform trials, gene therapies, and AI-driven discovery are improving efficiency and return on investment. Strategic funding of ALS research not only accelerates scientific progress but also promises long-term economic savings by reducing care costs and productivity losses. als.COMMUNITY is a free, one-stop platform for everyone impacted by ALS. We bring together patients, caregivers, family, clinicians, and researchers to share, learn, and connect. Join our community today: www.als.community Follow Us: Instagram: https://www.instagram.com/als.community/ Facebook: https://www.facebook.com/als.community #ALS

Continue reading on website
Other news

ALS Exercise and Movement

January 30, 2026
Exercise can play a meaningful role in supporting mobility, energy, and quality of life for individuals living with ALS and their families. This comprehensive guide explores safe, adaptive exercise options for ALS, including aerobic activity, strength training, stretching, balance, respiratory exercises, and aquatic therapy. Emphasizing personalized routines, professional guidance, and adaptive eq

Qalsody Economics and ALS Gene Therapy

January 30, 2026
Qalsody (tofersen), the first FDA-approved gene therapy for ALS targeting SOD1 mutations, highlights both the promise and the economic challenges of rare-disease innovation. Developed over more than a decade by Ionis Pharmaceuticals and commercialized by Biogen, Qalsody is estimated to have cost $4–5 billion to bring to market, driven by complex science and a very small patient population. Despite